Anticancer Bioscience Announces its First Granted US Patent for Synthetic Lethal Approach to Identifying Novel Cancer Treatments

Anticancer Bioscience Announces its First Granted US Patent for Synthetic Lethal Approach to Identifying Novel Cancer Treatments

Chengdu, China, September 9, 2021 – Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today its first granted US patent (11104633), entitled “cancer treatment using compounds that selectively target polyploid cancer cells for disruption”, which was issued by the US Patent and Trademark Office (USPTO) on August 31.

The method covered in this patent has been used to identify compounds that selectively kill polyploid cells, the key to the discovery of inhibitors of MYC, overexpression of which occurs in over half of tumors, and is correlated with poorly differentiated and aggressive cancer.

Dun Yang Ph.D., Founder, President, and CEO of ACB, said: “The grant of our first patent in the USA is a key milestone and underlines our innovative approach to identifying first-in-class and best-in-class approaches for the treatment of cancer, using synthetic lethal approaches. It forms part of our growing patent estate with nine additional patents pending, covering both methods and composition of matter.”

ACB is applying synthetic lethal approaches to develop targeted cancer therapies. These have the potential to be much safer and more effective than current therapies. ACB has access to world-leading cancer biology expertise and drug discovery platforms that enable the company to identify novel compounds that can target both genetic and epigenetic vulnerabilities of cancer cells. ACB has bespoke chemical compound libraries and has invested in developing one of the world’s largest natural product libraries, providing a rich screening resource for potential cancer therapeutics.

With five drug discovery programs, ACB is progressing rapidly through optimization to candidate selection toward IND enabling studies, with the aim of initiating two clinical trials in the USA in 2022.

-ENDS-

For further information, please contact:

At the company
Anticancer Bioscience:
bd@anticancerbio.com

Media Relations
Scius Communications
Sue Charles
+44 (0) 7968 726585
sue@sciuscommunications.com

About Anticancer Bioscience
Anticancer Bioscience (ACB) is an international private company, commercializing discoveries emerging from China’s world-leading cancer research at the J. Michael Bishop Institute of Cancer Research. With pioneers in synthetic lethal approaches to precision oncology and experts in MYC biology and cell division, ACB was founded in 2016 in Chengdu, China. ACB is based on over 20 years of collaborative research between the founder Dr. Dun Yang and his Nobel laureate mentor Dr. J. Michael Bishop. It has raised CNY131M (around USD21M) and has around 50 employees in Chengdu, China, Hyderabad, India, Sydney, Australia, St Andrews, UK, and San Francisco, USA.

Follow us on LinkedIn and Twitter.

9 thoughts on “Anticancer Bioscience Announces its First Granted US Patent for Synthetic Lethal Approach to Identifying Novel Cancer Treatments”

  1. Next time I read a blog, Hopefully it wont fail me as much as this particular one. I mean, Yes, it was my choice to read, however I really believed you would have something helpful to talk about. All I hear is a bunch of whining about something you could fix if you werent too busy searching for attention.

  2. May I just say what a comfort to uncover somebody who truly knows what theyre talking about on the internet. You actually know how to bring a problem to light and make it important. More and more people should look at this and understand this side of the story. Its surprising you arent more popular because you certainly have the gift.

  3. I don’t need to tell you how important it is to optimize every step in your SEO pipeline. But unfortunately, it’s nearly impossible to cut out time or money when it comes to getting good content. At least that’s what I thought until I came across Article Forge… Built by a team of AI researchers from MIT, Carnegie Mellon, Harvard, Article Forge is an artificial intelligence (AI) powered content writer that uses deep learning models to write entire articles about any topic in less than 60 seconds. Their team trained AI models on millions of articles to teach Article Forge how to draw connections between topics so that each article it writes is relevant, interesting and useful. All their hard work means you just enter a few keywords and Article Forge will write a complete article from scratch making sure every thought flows naturally into the next, resulting in readable, high quality, and unique content. Put simply, this is a secret weapon for anyone who needs content. I get how impossible that sounds so you need to see how Article Forge writes a complete article in less than 60 seconds! order here.

  4. Use artificial intelligence to cut turnaround time, extend your budget, and create more high-quality content that Google and readers will love. How It Works? WordAi is extremely fast and intuitive. Just enter your content, click rewrite, and in a matter of seconds, WordAi will rewrite an entire piece of content for you. WordAi comes up with different ways to express the same ideas by rewriting every sentence from scratch. This not only removes duplicate content, it also makes the rewritten content read completely naturally. Scale Your Business Make your entire content production process 10x more efficient. Use AI to create more high-quality, unique content that impresses clients and engages readers, all without having to put in more hours Register here and get a bonus.

  5. I was extremely pleased to discover this page. I want to to thank you for ones time due to this wonderful read!! I definitely appreciated every part of it and I have you bookmarked to look at new information on your web site.

Comments are closed.